Lupin Launches Ajaduo M Forte, a Triple Fixed-Dose Combination of Empagliflozin, Linagliptin, and Metformin Extended Release (ER)
Global pharmaceutical company Lupin Limited has announced the launch of Ajaduo M Forte, a novel triple fixed-dose combination (FDC) therapy for the management of Type 2 Diabetes Mellitus (T2DM) in India.
Ajaduo M Forte combines three well-established agents- Empagliflozin, Linagliptin, and Metformin Extended Release (ER)- into a single daily tablet, simplifying treatment regimens for patients struggling with diabetes and its associated complications.
The product will be available in two strengths:
- Ajaduo M Forte 25: Empagliflozin 25 mg + Linagliptin 5 mg + Metformin ER 1000 mg at 21 Rs/ Tab
- Ajaduo M Forte 10: Empagliflozin 10 mg + Linagliptin 5 mg + Metformin ER 1000 mg at 19 Rs/Tab
Empagliflozin, an SGLT2 inhibitor, promotes urinary glucose excretion and offers cardiovascular and renal benefits. Linagliptin, a DPP-4 inhibitor, enhances incretin levels to improve insulin secretion and reduce glucagon release. Metformin ER improves insulin sensitivity and suppresses hepatic glucose production.
With its focused Fixed dose combinations, Ajaduo M Forte specifically targets multiple pathophysiological defects described in the Ominous Octet model, addressing key contributors such as insulin resistance, beta-cell dysfunction, and increased renal glucose reabsorption. It is the only USFDA-approved fixed-dose triple combination of Empagliflozin, Linagliptin, and Metformin, providing a comprehensive approach to glycemic control. The formulation aligns with globally recognized guidelines, including those issued by the ADA/EASD and RSSDI, reinforcing its clinical relevance and utility in modern diabetes management.
Commenting on the launch, Mr Gagan Arora, Vice President Sales and Marketing, “Ajaduo M Forte reflects our commitment to delivering innovative, patient-centric solutions. This triple combination simplifies therapy while offering robust efficacy aligned with international recommendations, enabling better long-term outcomes for diabetes patients in India.”
With Empagliflozin going off-patent, Lupin has strategically expanded its diabetes portfolio by launching Ajaduo, a fixed-dose combination (FDC) of Empagliflozin and Linagliptin, available in Ajaduo 10/5 and Ajaduo 25/5. Additionally, the company has introduced Ajaduo M Forte, a triple FDC of Empagliflozin, Linagliptin, and Metformin Extended Release, available in Ajaduo M Forte 25 and Ajaduo M Forte 10.
You can read about it at the link below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.